



Application of: Thiede, et al.  
Serial No.: 09/830,139  
Filed: November 20, 2001  
For: In Utero Transplantation of Human Mesenchymal Stem Cells  
Group: 1632  
Examiner: Voitach

Commissioner for Patents  
Box 1460  
Alexandria, VA 22313-1450

### **BRIEF ON APPEAL**

Sir:

This is an Appeal from the Final Rejection dated October 4, 2004.

### **REAL PARTY IN INTEREST**

The real party in interest is Osiris Therapeutics, Inc., the assignee of the claimed subject matter of the above-identified application.

### **RELATED APPEALS AND INTERFERENCES**

There are no related appeals and interferences.

### **STATUS OF CLAIMS**

Claims 1-5 and 9-27 are withdrawn from consideration.

Claims 6-8 are pending, stand finally rejected, and are before the Board on appeal.

These claims are listed in the Appendix attached hereto.

### **STATUS OF AMENDMENTS**

No amendments after the Final Rejection have been filed.

## **SUMMARY OF CLAIMED SUBJECT MATTER**

The present invention, as defined broadly in Claim 6, is directed to a method of engrafting mesenchymal stem cells, comprising administering mesenchymal stem cells to a fetus in utero. Support is found in the specification at Pages 3 and 4, and in the Examples at Pages 13-29.

As defined in Claim 7, the fetus is a non-human fetus. Support for Claim 7 is found in the specification at Page 12, and in the Examples at Pages 13-29.

As defined in Claim 8, the mesenchymal stem cells are human mesenchymal stem cells. Support for Claim 8 is found in the specification at Pages 6, 7, and 12, and in the Examples at Pages 13-29.

## **GROUND OF REJECTION TO BE REVIEWED ON APPEAL**

The following grounds of rejection are to be reviewed by the Board on Appeal:

- (i) the rejection of Claims 6-8 under 35 U.S.C. 101 because the claimed invention is not supported by a well-asserted utility or a well-established utility; and
- (ii) the rejection of Claims 6-8 under 35 U.S.C. 112, first paragraph, in that the specification provides insufficient guidance and teaching on how to accomplish the proposed utilities specifically set forth.

## **ARGUMENT**

With respect to the rejection under 35 U.S.C. 101, Examiner has admitted that the specification teaches and provides evidence that mesenchymal stem cells can be

transplanted in utero, and that the implanted cells will become distributed throughout the fetus, and in some cases, the cells differentiate into various cell types.

As indicated in the specification, human mesenchymal stem cells were given to fetal sheep at 65 days or 85 days gestation. Tissue was harvested from the sheep at 2 weeks, 2 months, or 5 months after transplantation of the human mesenchymal stem cells.

Two weeks after the transplantation of the human mesenchymal stem cells, human  $\beta$ -2 microglobulin DNA was detected in liver, spleen, lung, bone marrow, thymus, brain, heart, and blood in both the sheep that were given the mesenchymal stem cells at 65 days gestation, and the sheep that were given the mesenchymal stem cells at 85 days gestation.

After 2 months, human DNA was detected in liver, spleen, lung, bone marrow, thymus, heart, skeletal muscle, blood, and cartilage of fetuses transplanted with the human mesenchymal stem cells at 65 days gestation. In the fetuses transplanted at 85 days gestation, human DNA was detected after 2 months in the spleen, bone marrow, thymus, and blood.

At 5 months after the in utero transplantation of the human mesenchymal stem cells, i.e., at 3 months after birth, human DNA was detected in the bone marrow, thymus, spleen, lung, cartilage, and blood of fetuses transplanted at 65 days gestation, and in the heart, brain, skeletal muscle, and blood of fetuses transplanted at 85 days gestation.

Furthermore, as discussed at Pages 22 and 23 of the specification, the human mesenchymal stem cells, after the administration thereof to fetal sheep, were found to have differentiated into cardiomyocytes, chondrocytes, bone marrow stromal cells, and thymic stromal cells.

In particular, at 2 and 5 months after in utero transplantation, human cells were detected in the cardiac muscle of sheep fetuses transplanted at 65 and 85 days gestation. Such cells had similar morphology to the surrounding ovine cardiomyocytes.

In addition, chondrocyte differentiation was identified by the finding of human  $\beta$ -2 microglobulin positive cells in the cartilage lacunae of lambs transplanted with human mesenchymal stem cells at 65 days gestation, and harvested at 2 months or 5 months after transplantation.

At 5 months after in utero transplantation of human mesenchymal stem cells, many human cells were seen in the bone marrow of the sheep, and were demonstrated to express CD23. The human CD23 positive cells appeared to be large cells clustered in areas with sheep hematopoietic elements, consistent with bone marrow stroma.

Furthermore, at 5 months after in utero transplantation of human mesenchymal stem cells, multiple human cells were detected in the thymus that expressed CD74, an MHC associated invariant chain expressed on thymic stromal cells. These cells were large and were similar in morphologic appearance to nearby ovine thymic epithelium.

At Page 24, it is noted that in five fetal sheep at 65 days gestation in which tail wounds were created and which were given human mesenchymal stem cells human DNA was found in the tail wounds, and such cells in which the human DNA was found had the morphological appearance of fibroblasts.

Thus, Applicants clearly have demonstrated that one can transplant mesenchymal stem cells into a fetus in utero, and that the mesenchymal stem cells will engraft in the fetus, and may differentiate into various cell types in the fetus. Thus, the results shown in the specification provide a basis for employing prenatal mesenchymal stem cell

transplantation in order to provide a reservoir of normal stem cells to replace defective cells as they become damaged in degenerative diseases with progressive cellular and organ damage, as stated at Page 25 of the specification.

Therefore, contrary to the Examiner's assertions, the claimed method has a specific and substantial asserted utility.

The Examiner again is reminded that the claims define a method of engrafting mesenchymal stem cells, and through the examples, Applicants have demonstrated that one may engraft mesenchymal stem cells into a fetus, and further that such engrafted mesenchymal stem cells may differentiate in the fetus into various cell types. Furthermore, the Examiner is reminded that Applicants need not demonstrate every possible utility of the invention, and the burden is upon the Examiner to show that the claimed method has no utility. The case law is clear that not all embodiments encompassed within a claim must be operable for the claim to be valid. (Ex parte Mark, 12 U.S. P.Q. 2d 1904 (Bd. App. Int. 1989).) The Examiner has not met such burden in that, in order to assert that the claimed invention has no utility, the Examiner has provided nothing more than statements of sheer speculation.

Thus, because Applicants have demonstrated engraftment and differentiation of mesenchymal stem cells when such mesenchymal stem cells have been transplanted into a fetus, Applicants have demonstrated a utility for the claimed invention, especially where the Examiner has failed to show that the claimed invention does not have any utility. Therefore, Claims 6-8 comply with the requirements of 35 U.S.C. 101, and it is therefore respectfully requested that the rejection under 35 U.S.C. 101 be reversed.

With respect to the rejection under 35 U.S.C. 112, first paragraph, as stated hereinabove, Applicants have demonstrated that mesenchymal stem cells, when administered to a fetus, will engraft in the fetus, and such mesenchymal stem cells will differentiate into various cell types. Thus, the mesenchymal stem cells may be used to provide a reservoir of normal stem cells to replace defective cells as they become damaged in degenerative diseases with progressive cellular and organ damage. The examples have shown that mesenchymal stem cells, when transplanted into a fetus, may differentiate into cardiomyocytes, chondrocytes, bone marrow stromal cells, and thymic stromal cells. Thus, Applicants have proven the principle that one can transplant mesenchymal stem cells into a fetus, whereby the mesenchymal stem cells will engraft in the fetus, and such mesenchymal stem cells will differentiate into various cell types. Thus, there is a reasonable expectation that one can administer mesenchymal stem cells to a fetus, and that such mesenchymal stem cells will engraft and then differentiate in vivo into various cell types, and thus such mesenchymal stem cells may be used to replace defective cells. The working examples, therefore, provide sufficient guidance with respect to practicing the claimed invention, and also provide one skilled in the art with a reasonable expectation of success.

The Examiner, in holding that the specification does not provide an enabling disclosure, has provided nothing more than statements of sheer speculation. Such speculative statements are insufficient to support the Examiner's holding.

Therefore, for the above reasons and others, the specification provides an enabling disclosure, and it is therefore respectfully requested that the rejection under 35 U.S.C. 112, first paragraph, be reversed.

For the above reasons and others, it is therefore respectfully requested that the rejections under 35 U.S.C. 101 and 35 U.S.C. 112, first paragraph, be reversed.

Respectfully submitted,

A handwritten signature in cursive script, reading "Raymond J. Lillie". The signature is written in black ink and is positioned above the printed name and registration number.

Raymond J. Lillie  
Registration No. 31,778

## **APPENDIX - CLAIMS ON APPEAL**

6. A method of engrafting mesenchymal stem cells, comprising: administering mesenchymal stem cells to a fetus in utero.
7. The method of Claim 6 wherein said fetus is non-human.
8. The method of Claim 7 wherein said mesenchymal stem cells are human.

#263458 v1